Neoadjuvant Chemoimmunotherapy Achieved a Pathologic Complete Response in Stage IIIA Lung Adenocarcinoma Harboring RET Fusion: a Case Report
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10791793/
Neoadjuvant chemoimmunotherapy has demonstrated significant benefit for resectable non-small-cell lung cancer (NSCLC) excluding known EGFR/ALK genetic alterations. Recent evidence has shown that neoadjuvant chemoimmunotherapy could be clinically valuable ...
Researchers provided the first direct evidence that resectable NSCLC with RET fusion and strongly positive PD-L1 staining had a significant response to neoadjuvant chemoimmunotherapy.
Clinical Characteristics and Progression of Pre-/Minimally Invasive Lung Adenocarcinoma Harboring ALK or RET Rearrangements: a Retrospective Cohort Study
Source : https://tlcr.amegroups.org/article/view/81616/html
Clinical characteristics and progression of pre-/minimally invasive lung adenocarcinoma harboring ALK or RET rearrangements: a retrospective cohort study
ALK-/RET-positive pre-/minimally invasive lung adenocarcinomas were mostly characterized as mixed ground-glass opacities with cystic airspace developing rapid nodule progression, and no recurrence occurred during long-term follow-up after resection.
Selective RET Inhibitors (SRIs) in Cancer: a Journey From Multi-Kinase Inhibitors to the Next Generation of SRIs
Source : https://www.mdpi.com/2072-6694/16/1/31
RET is a receptor tyrosine kinase that plays an important role in the development of neurons and kidneys. The gene encoding the rearranged-during-transfection (RET) receptor tyrosine kinase was first discovered...
Patients with NSCLC or MTC who progressed after initial response to selpercatinib or pralsetinib revealed 3 emerging distinct resistance mutations, G810 R/S/C, within the RET solvent front.
Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma
Source : https://pubmed.ncbi.nlm.nih.gov/38127829/
Bypass resistance may be the most frequent mechanism of progression under RETi. A more aggressive histology may arise following RETi and warrants further investigation.
Post-RET inhibitor profiles revealed a bypass mechanism of resistance in 75% of the cases, including RAS mutations (50%), FGFR2 and ALK fusions, and MYC p.P44L.
Therapeutic Strategy Using Novel RET/YES1 Dual-Target Inhibitor in Lung Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38198957/
Lung cancer represents a significant global health concern and stands as the leading cause of cancer-related mortality worldwide. The identification of specific genomic alterations such as EGFR and KRAS in...
A novel dual-target inhibitor effectively targeted RET and YES1, thereby demonstrating its potential to impede the growth and metastasis of RET-rearrangement lung cancer.